Loading clinical trials...

Duloxetine for the Treatment of Generalized Anxiety Disorder | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Duloxetine for the Treatment of Generalized Anxiety Disorder

Duloxetine Versus Placebo in the Treatment of Patients With Generalized Anxiety Disorder in China

NCT00803361•Eli Lilly and Company

View on ClinicalTrials.gov

Summary

This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Psychiatric Diagnosis of generalized anxiety disorder (GAD)
•Outpatients
•Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis for GAD
•Clinical Global Impression (CGI) of Severity Score of at least moderate
•Sheehan Disability Scale (SDS) Global Functioning Impairment Score \>= 12

Exclusion Criteria

•Pregnancy or breast feeding
•Serious medical illness
•Other primary psychiatric diagnoses, such as major depressive disorder or substance abuse disorder within the past 6 months
•panic disorder, post-traumatic stress disorder (PTSD), or eating disorder in the last year
•lifetime history of bipolar or psychosis
•Any unstable serious medical condition for which duloxetine would not be allowed
•Any use of medications that are not allowed

Locations (7)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Beijing, China

Guangzhou, China

Hangzhou, China

Kunming, China

Nanjing, China

Shanghai, China

Xi'an, China

Key Dates

Start Date

December 1, 2008

Primary Completion Date

January 1, 2010

Completion Date

January 1, 2010

Last Updated

December 17, 2010

Enrollment

210

ACTUAL participants

Conditions

Generalized Anxiety Disorder

Interventions

Duloxetine

DRUG

Placebo

DRUG

Transcranial Alternating Current Stimulation for Generalized Anxiety Disorder and Insomnia: An Open-Label Pilot Study

NCT07429578

Generalized Anxiety Disorder (GAD)Chronic Insomnia

View study

RECRUITINGNA

Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders

NCT06661460

ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)Specific Phobia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 17, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Duloxetine for the Treatment of Generalized Anxiety Disorder

Inclusion Criteria

Exclusion Criteria

Transcranial Alternating Current Stimulation for Generalized Anxiety Disorder and Insomnia: An Open-Label Pilot Study

Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder

Teletherapy vs. In-Person Cognitive Behavioral Therapy for Generalized Anxiety Disorder

Electroclinical Correlation of Anxiety